Trials / Completed
CompletedNCT03988335
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Aristea Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RIST4721 | RIST4721 oral solution |
| DRUG | Placebo | Placebo oral solution |
Timeline
- Start date
- 2019-02-13
- Primary completion
- 2019-11-05
- Completion
- 2019-11-19
- First posted
- 2019-06-17
- Last updated
- 2022-04-05
- Results posted
- 2022-03-03
Locations
17 sites across 2 countries: Canada, Germany
Source: ClinicalTrials.gov record NCT03988335. Inclusion in this directory is not an endorsement.